ArticlePediatrics international : official journal of the Japan Pediatric Society
Successful long-term survival of patients with trisomy 18 and hepatoblastoma after cardiac surgery.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Successful long-term survival of patients with trisomy 18 and hepatoblastoma after cardiac surgery.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost patients with trisomy 18 (18T) die of cardiac or other severe anomalies within the first few years. Although surgical intervention for cardiac lesions or other diseases has improved these patients' prognoses in recent years, some survivors face the risk of developing neoplasms, such as hepatoblastoma. However, the treatment strategy remains controversial because of the poor prognosis. We evaluated the merits of aggressive therapeutic interventions for malignant tumors in 18T patients.
methodsWe encountered five patients who underwent hepatoblastoma treatment within the last 11 years. These patients, four girls and one boy, were aged 10 months to 3 years and 9 months at diagnosis; all had previously undergone cardiac interventions.
resultsThree patients were diagnosed with PRETEXT I, whereas the remaining two were diagnosed with PRETEXT II and IV. Primary resection of the tumor was conducted in three patients with PRETEXT I, followed by chemotherapy in two patients. Open biopsy and neoadjuvant chemotherapy were administered in two patients (PRETEXT II and IV), and subsequent tumor resection could be conducted only in the PRETEXT II patient and not in the PRETEXT IV patient. Four patients who underwent liver resection achieved disease-free survival for 6-10 years postoperatively, and the PRETEXT IV patient did not have tumor regrowth for approximately 2 years and died of another cause. All treatments, including chemotherapy and surgical resection, were administered safely.
conclusionsSurgical treatment of hepatoblastoma in 18 T patients can be performed safely after cardiac intervention, after obtaining informed consent regarding the associated risks and benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.